Jenny Johnson sees opportunity in the front end of the curve for big tech debt tied to the AI buildout. The combination of healthy cash generation and sturdy balance sheets makes near-term obligations attractive, she said. Longer maturities, by contrast, lean more on where the technology ultimately lands, which is still uncertain. Or as she put it: "Going longer-term on those would be a little bit more scary for me." Her punch line on yields was just as clear: "But you know, two-year paper at nine, pretty dang good!"
Johnson noted that these companies are not relying solely on conventional bank or bond financing. Today's structures also include arrangements kept off the balance sheet, supported by hyperscalers and by suppliers that in some cases act as lenders. That mix makes the capital stack "very complex," she said, which matters for how investors evaluate risk and repayment.
When a major asset manager flags a crowded trade, positioning is the story. Market Briefs covers allocation calls free every morning.
Johnson said the AI push has not yet reshaped most traditional industries. "The AI story has not played out at all in sectors and traditional businesses," she said. "That is to come." One area where she already sees signs of progress is healthcare, where firms report fatter pipelines of potential drug discoveries and more precise clinical trials that could mean higher efficacy and quicker regulatory approvals. Relatedly, Bloomberg reported that AI spending may pave the way for upgrades to about $24 billion in Asian tech bonds.
If you are watching AI from the sidelines, Johnson's take boils down to timing and risk. Near-term tech paper may offer compelling income while the longer-term payoff from AI remains uncertain. And with funding growing more intricate, understanding who ultimately stands behind a company's obligations matters. The headline for regular investors: the AI wave is still building, and the safer plays today might be in the parts of the market that pay you while you wait.
Contrarian views are worth hearing precisely when they feel wrong. Get the free Market Briefs daily newsletter and weigh them.
